Chinese authorities have approved a new COVID-19 vaccine candidate
for human trials, the Institute of Microbiology under the Chinese
Academy of Sciences, said in a statement. The recombinant protein vaccine was issued with a clinical research
permit from the National Medical Products Administration on June 19,
according to the institute, which is the vaccine's main developer. Researchers will start phase-1 clinical trials in hospitals in
Chongqing and Beijing, to determine whether the vaccine is safe for use
on humans, its co-developer Anhui Zhifei Longcom Biopharmaceutical Co.,
Ltd. confirmed. It represents the third type of COVID-19 vaccine developed by Chinese
researchers to enter clinical trials. One adenovirus vaccine and four
inactivated vaccines have previously been approved for human tests in
China, with some having just cleared phase-2 trials.
|